Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.
The company's shares are trading at their lowest since August 2023. Source: xStation
US100 tries to recover🗽Sell-off hits uranium stocks
Zions Bancorp rebound after sharp US regional bank stocks sell-off 📈
DE40: European markets decline due to concerns about the U.S. banking sector
Zions Bancorporation Shares Under Pressure After Loan Write-Down!